Drugs / ATDC_Nantes
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1/2 | NCT02252055 | Mar 2015 → Nov 2018 | end stage renal failure | Nantes University Hospital | Completed | No outcome recorded |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | ATDC_Nantes | ClinicalTrials.gov intervention name — accepted as the source's own label NCT02252055 ↗ |
| Known as | ATDC | “Here, we present the first phase I clinical trial results using human autologous tolerogenic dendritic cells (ATDC) in kidney transplantation.” PMID 36306921 ↗ Oct 2022 |
| Modality | Cell therapy | “human autologous tolerogenic dendritic cells (ATDC)” PMID 36306921 ↗ Oct 2022 |
| Route | Intravenous | “ATDC treatment (1 x 106 cells/kg BW slow peripheral venous) occurs the day before transplantation” NCT02252055 ↗ |